Tarsier Pharma Ltd. competitors & alternatives

Tarsus Pharmaceuticals, Inc.TARS · BiotechnologyIrvine, United States

72% matchPublicAI 4/100 ▼Green 6/100 ▼

Similar biotechnology company

Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to advancing and commercializing innovative therapies, primarily focusing on ocular conditions. Its leading investigational drug, TP-03, a novel treatment currently in Phase III trials, is being developed to address blepharitis specifically caused by Demodex mite infestations, as well as meibomian gland disease. Beyond this, Tarsus is also progressing TP-04 for rosacea and TP-05, which targets Lyme disease prevention and aims to reduce community-level malaria. A core element of its development strategy involves lotilaner, a compound utilized to tackle a variety of human diseases across diverse therapeutic areas, encompassing eye care, dermatology, and other medical fields. Established in 2016, the company maintains its headquarters in Irvine, California.

Biotech

BioLight Life Sciences Ltd. is an ophthalmic firm dedicated to discovering, developing, and bringing to market innovative products and pipeline candidates designed to tackle various eye-related ailments. Its portfolio and development pipeline include DiagnosTear's TeaRx, a diagnostic platform analyzing tear fluid components to identify frontal eye diseases, and Peripherex, offering solutions for both at-home and clinical diagnosis and monitoring of peripheral vision loss, crucial for conditions like glaucoma. For glaucoma, BioLight features ViSci (an Eye D technology utilizing a subconjunctival implant), Belkin Vision's rapid, automated laser system for effective intraocular pressure reduction, and Sanoculis, which is advancing a novel surgical approach. The company also encompasses OphRx, focused on developing pharmaceutical treatments for ocular disorders; AEYE, which designs artificial intelligence-powered solutions for diverse retinal conditions; and Tarsier, working on TRS 01, a platform-based treatment for uveitis in patients with elevated intraocular pressure. Founded in 2005, the Tel Aviv, Israel-based company operated as Bio Light Israeli Life Sciences Investments Ltd. until its rebranding to BioLight Life Sciences Ltd. in February 2016.

Tavo BiotherapeuticsBiotechnologyUnited States

69% match

Similar biotechnology company

Tavo Biotherapeutics is a biotechnology company headquartered in Laguna Beach, California. The company focuses on driving breakthrough pharmaceutical innovations and developing novel treatments for glaucoma and vision preservation.

Broadwing BioBiotechnology

69% match

Similar biotechnology company

Broadwing Bio is a biotechnology company that develops antibody-based therapies to treat major causes of adult vision loss, specifically focusing on Geographic Atrophy and Glaucoma. The company utilizes genetics-driven insights to target ocular diseases and preserve vision for patients.

Biotech

Oculis Holding AG is a biopharmaceutical company in the clinical development stage, specializing in the creation of innovative eye drop medications for various ocular conditions, addressing both the anterior and posterior segments of the eye. A key asset in its therapeutic portfolio is OCS-01, a topical formulation of dexamethasone, currently progressing through Phase 3 clinical trials for the management of diabetic macular edema. Additionally, OCS-02, a topically administered biological candidate, is engaged in Phase 2b clinical studies to treat keratoconjunctivitis sicca, commonly known as dry eye disease. The company is also advancing OCS-05, an innovative neuroprotective agent, which targets acute optic neuritis and an array of other neuro-ophthalmic disorders, including glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. This enterprise maintains its headquarters in Zug, Switzerland.

Similar biotechnology company

Kiora Pharmaceuticals, Inc., a specialty pharmaceutical firm operating at the clinical stage, is dedicated to the creation and commercialization of treatments for various ophthalmic conditions across the United States. Its flagship therapeutic candidate, KIO-301, is a groundbreaking small molecule undergoing Phase 1 clinical trials. This innovative "photoswitch" aims to revitalize vision in individuals suffering from both inherited and age-related forms of retinal degeneration. The company's pipeline also includes KIO-101, an eye drop currently in Phase 2 trials for addressing the ocular manifestations of rheumatoid arthritis, as well as non-infectious posterior uveitis. Furthermore, Kiora is advancing KIO-201, another eye drop, which is in Phase 3 clinical trials, designed to facilitate corneal wound healing following PRK surgery. Established in 1998, the company adopted its current name in November 2021, having previously operated as Eyegate Pharmaceuticals, Inc. Kiora Pharmaceuticals maintains its corporate headquarters in Salt Lake City, Utah.

AlkeusBiotechUnited States

68% match

Biotech

Alkeus Pharmaceuticals, Inc. is a late-stage biopharmaceutical company based in Cambridge, Massachusetts, dedicated to developing treatments that preserve the sight of individuals impacted by severe eye diseases.

HealomeBiotechUnited Kingdom

67% match

Biotech

Healome Therapeutics Ltd is an eye care and ophthalmology therapeutics company founded in 2021 and headquartered in Birmingham, United Kingdom. The company develops safer and more effective ocular drug delivery treatments for vision-threatening ocular surface diseases.

MCAL Therapeutics Inc.BiotechnologyUnited States

67% matchPrivate

Similar biotechnology company

MCAL Therapeutics Inc. is a biotechnology company developing synthetic, rabbit-inspired lipid eye drops and extended-release drug delivery platforms. Its lead candidate, MCAL-201, is designed to treat evaporative dry eye disease by restoring the tear film's protective lipid barrier.

Aperta Biosciences, LLCBiotechnologyUnited States

67% matchPrivate

Similar biotechnology company

Aperta Biosciences is a biopharmaceutical company that develops novel therapeutics for ocular surface diseases, including blepharitis, ocular rosacea, meibomian gland dysfunction, and dry eye disease. The company's lead candidate, APT-001, is an ophthalmic suspension designed to treat the underlying cause of blepharitis by eradicating ocular Demodex infestations.

Similar biotechnology company

Eyevensys is a biotechnology company developing non-viral gene therapies for ophthalmic diseases. Its platform uses electro-transfection of the eye’s ciliary muscle to enable sustained local production of therapeutic proteins for retinal and other ocular conditions.

Neurock Pharmaceuticals Inc.BiotechnologyUnited States

67% match

Similar biotechnology company

Neurotech Pharmaceuticals is a biotechnology company that develops transformative therapies for chronic eye diseases, utilizing its proprietary Encapsulated Cell Therapy platform. The company serves patients with conditions such as Macular Telangiectasia Type 2 by providing advanced treatments designed to protect against progressive vision loss.